• Prescribing Information
  • Medical Information

    • Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.

    Click here to learn how we are responding.

    Available with a 2-dose option1​​​​​​​

    I thought I had the flu.

    It was actually serogroup B meningococcal disease (MenB), and it almost killed me.

    Learn more about the risk of MenB

    Pfizer TruSupport

    •  
    •  
    • Ordering options
    • Patient coverage confirmation​​​​​​​
    • Essential tools​​​​​​​
    • ​​​​​​​Resources for your practice​​​​​​​
    •  
    •  
    Find out about TruSupport

    CDC* recommendations

    ​​​​​​​MenB vaccination is part of the CDC 16-year-old vaccination platform.2​​​​​​​

    Read the recommendations

    *CDC=Centers for Disease Control and Prevention.

    The science behind TRUMENBA

    Only TRUMENBA targets both subfamilies, A and B, of fHBP.1​​​​​​​​​​​​​​

    See the science

    ** This is an optional area where footnotes can live.

    TRUMENBA clinical studies

    TRUMENBA is the only MenB vaccine that demonstrated cross-coverage of diverse MenB strains by targeting both subfamilies, A and B, of fHBP.1​​​​​​​​​​​​

    See the data

    ** This is an optional area where footnotes can live.

    Contact your Pfizer Sales Representative or call a Vaccine Specialist at 
    ​​​​​​​1-844-439-2571.

    References:
    1. Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc.; 2019.
    2. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2021. Centers for Disease Control and Prevention website. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. Accessed July 6, 2020.

    Indication

    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed
    • Severe allergic reaction after a previous dose of Trumenba is a contraindication
    • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
    • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
    • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
    • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
    • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%). Nausea was reported in up to 24% of adolescents in early phase studies
    • Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
    • Safety and effectiveness have not been established in pregnant women
    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed

    Please see full Prescribing Information.​​​​​​​